Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg in a body sample are disclosed.

Abstract: Fragments of human Factor VIII:C which bind to antibody inhibitors of Factor VIII in patients afflicted with such inhibitors are disclosed. The method of treating Factor VIII inhibitors, by administering one or more of these fragments, is also disclosed.

Abstract: A vaccine against a microbial pathogen comprised of a live, immunogenic but prototrophic and avirulent mutant strain of the selected microbial pathogen in an amount effective to confer immunity. A method of obtaining a vaccine that induces a heightened cellular and humoral immune response to one of a variety of microbial pathogens in a warm blooded animal. A method for isolation of an avirulent strain of a selected pathogenic microorganism.

Abstract: Synthetic polypeptides containing about 10 to about 35 amino acid residues corresponding in sequence to the amino acid residue sequence of about position 35 to about position 95 from the amino-terminus of the B-subunit of the heat-labile enterotoxin of Escherichia coli are disclosed along with composite polypeptides containing the polypeptide sequence of the heat-stable Escherichia coli enterotoxin, as are polymers containing the synthetic polypeptide and composite polypeptide as repeating units. The polypeptides are useful as conjugates coupled to a carrier or as a polymer as the active ingredient of an inoculum to raise antibodies and for protecting an animal host against infection by heat-labile enterotoxin-producing bacteria.

Abstract: Aotus trivirgatus interspecies hybridomas, their monoclonal receptors and methods of preparation and use are disclosed. The hybridomas are prepared by fusion of Aotus antibody-producing cells with myeloma cells containing about an equal number of chromosomes per cell. The resulting hybridomas are stable and secrete Aotus receptors. Particular receptors that immunoreact with antigenic proteins of Plasmodium falciparum shizonts and merozoites are disclosed.

Abstract: An antimicrobial composition and its method of use are disclosed. The composition contains an in vivo effective amount of an antibiotic and a potentiating amount of an immune response-enhancing agent. The immune response-enhancing agent corresponds in structure to a formula selected from ##STR1## where X is O or S; Z is N--R.sub.2, O or S; R.sub.1, R.sub.2 and R.sub.3 are substituted groups; and R.sub.4 is an aldoglycosidyl radical.

Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to tuberculous mycobacteria are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic polypeptide having about 13 or 14 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the thirteen or fourteen amino acid reside sequence (AlaLysValAsnIleLysProLeuGluAspLysIleCys) or (CysAlaLysValAsnIleLysProLeuGluAspLysIleCys). When linked to a carrier and introduced in an effective amount into a mammalian host, the polypeptide is capable of inducing production of antibodies that immunoreact with an antigen to a tuberculous mycobacterium.

Abstract: A vascular prosthesis for implantation in a living mammalian body and a method for producing same are disclosed. The vascular prosthesis has a hydrophobic polymeric layer on its luminal surface defining a substantially non-thrombogenic flow surface. The polymeric material of the layer defining the flow surface exhibits a rate of platelet consumption of less than about 20.times.10.sup.8 platelets/cm.sup.2 .multidot.day.

Abstract: A method is discussed for the production of anti-receptor antibodies and to the detection and isolation of naturally occurring anti-receptor antibodies in animals and humans. The anti-receptor antibodies can be isolated from polyvalent anti-receptor antisera by immunodepletion of anti-immunoglobulin antibodies or by a single affinity purification step using antibody raised to an antigen recognized by the receptor.

Abstract: A lymphocyte-activating polypeptide, a composition containing the polypeptide and a method for using the composition are disclosed. The polypeptide contains a sequence of 4 to about 11 residues and corresponds in sequence to the formula:(B).sub.b -Leu-Pro-Pro-Ser-(Y).sub.y.

Abstract: Peptides of the general formulaH.sub.2 N-(Ch)-Arg-Gly-Asp-(Cx)-Hand the derivatives thereof described herein, wherein (Cx) and (Ch) each contains 1 to 20 amino acid residues and (Ch) contains at least one Lys or Arg residue, or at least one of each, inhibit platelet-fibrinogen binding and platelet-platelet aggregation and are thus useful inhibitors of cell adhesion.

Abstract: A single polypeptide antigen that includes the amino acid residue sequence and epitope of a conformation-independent antigenic determinant and the amino acid residue sequence but lacks the epitope of a conformation-dependent antigenic determinant is disclosed as are methods of its manufacture and use and articles of manufacture using the same. The uses of the pre-S(2) region polypeptide encoded by the hepatitis B virus genome as a T cell proliferating agent and as a potentiator for enhancing the humoral immune response of animals that exhibit a low humoral response to an S region-containing immunogen are also disclosed.

Abstract: Monoclonal receptors that immunologically bind to human apolipoprotein A molecules, particularly apo-A-I and apo-A-II, are described as are their methods of use and articles of manufacture containing them.

Abstract: A non-human, mammalian monoclonal receptor produced and secreted by a hybridoma having the ATCC accession number HB 8568 and methods of preparing and using same, as well as diagnostics utilizing the receptor are disclosed. The monoclonal receptor reacts with cells such as human neuroectodermal tumors having ganglioside GD.sub.2 antigen expressed on their cellular membrane surfaces.

Abstract: A murine monoclonal antibody combining site produced by a hybridoma formed by fusion of cells from a myeloma cell line and lymphocytes that produce antibodies that react (1) with isolated human C3b receptor and (2) with C3b receptor-bearing cells from a mammal immunized with human C3b receptor is disclosed.

Abstract: The present invention relates to a leukemia-associated virus immunogens, vaccines, and assays. The immunogens are relatively short polypeptides with peptide sequences corresponding to the antigenic determinant domains of a leukemia-associated virus envelope protein. The immunogens when introduced into a host stimulate the production of antibodies which immunoreact with the polypeptides and the leukemia-associated virus.The immunogens may be used together with other components such as adjuvants to form immunizing compositions such as vaccines. The antibodies may be used together with other components in an assay system to detect the presence of a leukemia-associated virus antigen in a body fluid sample. The antibodies can also be used in the treatment of leukemia-associated virus infections.

Abstract: A phosphonamidate or phosphonate analog-ligand having a conformation that substantially corresponds to the conformation of a hydrolytic transition state of an amide or ester ligand is used to produce antibodies of predetermined specificity. The antibodies include an epitope that binds to and thereby stabilizes the tetrahedral carbon atom of the amide or ester hydrolysis transition state of the ligand to hydrolyze the ligand at a predetermined site.

Abstract: Active factor VIII:C coagulant polypeptides identified by partial amino acid sequences are disclosed.

Abstract: Antigens, immunogens, inocula, antibodies, diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. Each of the compounds, compositions, methods or systems contains a synthetic, random copolymer polypeptide having about 6 to about 40 residues, or an antibody containing site that immunoreacts with such a polypeptide. The polypeptide includes the five amino acid residue sequence -Gly-R.sup.1 -Gly-R.sup.2 -Gly-, wherein R.sup.1 and R.sup.2 are the same or different amino acid residues selected from the group consisting of Ala, Asn, Arg, Gly, Leu, Pro, Ser, and Thr, with the provision that R.sup.1 and R.sup.2 are not both Gly. The polypeptide contains at least 25 mole percent Gly residues, and when linked to a carrier and introduced in an effective amount into a mammalian host is capable of inducing production of antibodies that immunoreact with EBNA.

Abstract: Fragments of human Factor VIII:C which bind to antibody inhibitors of Factor VIII in patients afflicted with such inhibitors are disclosed. The method of treating Factor VIII inhibitors, by administering one or more of these fragments, is also disclosed.